# persona_off · bixbench · bix-33-q1

[All trial-1 traces](../../README.md)

- Trial: **1**; endpoint: **original**; attempt: **1**.
- Native status: **scored**; normalized native score: **0/100**.
- Recorded protocol: `researcher-review-v2`.
- Actor, simulator, and judge: **GPT-6 Astra, low reasoning**.
- Scope: chronological shared messages and handoff fields. Private tool logs, system prompts, evaluator references, and raw API requests are not included.
- A repaired endpoint belongs to the same trial; it is not an independent repeat. Zero scores and missing scientific submissions are retained.

## Shared conversation

### Event 1 — Simulator

**Message**

````text
Inspect the supplied files and any accompanying repository documentation only; do not perform the full analysis yet. Report the workbook structure, gene identifier fields, relevant significance and fold-change columns, and any documented DEG thresholds or treatment contrast definitions. Inspect relevant h5ad metadata as needed without loading the full expression matrix unnecessarily. Propose a reproducible approach to identify the immune cell type with the most significant post-versus-pre treatment DEGs, including handling of duplicate genes, missing values, and nonimmune worksheets. Distinguish documented methods from assumptions, especially the significance cutoff and whether an effect-size filter is required. Identify consequential uncertainties and the script/notebook artifact you propose to retain.
````

**Interaction**

````text
initial_request
````

**Phase**

````text
initial_inspection
````

**Action**

````text
continue
````

**Approve Approach**

````text
false
````

**Evidence**

````text
The supplied context lists cell-type-specific workbook sheets with p_val, avg_log2FC, pct.1, pct.2, and p_val_adj columns, but does not establish significance thresholds, gene identifier layout, or contrast details.
````

**Objectives Open**

````text
[
  "Inspect inputs and applicable methodological documentation.",
  "Agree on significance criteria and counting approach.",
  "Execute the agreed analysis and retain a reproducible artifact.",
  "Provide a concise answer identifying the immune cell type with the highest significant DEG count."
]
````

### Event 10 — Actor

**Answer**

````text
Inspection only is complete; no DEG counts or ranking have been calculated. Approval requested for the following reproducible analysis.

**Observed inputs and structure**
The workspace contains the two supplied data files and task.json; no accompanying README or analysis repository is present. The workbook has 25 cell-type worksheets, each with six columns: an unnamed first column containing gene symbols (e.g., MTRNR2L12, BAX), `p_val`, `avg_log2FC`, `pct.1`, `pct.2`, and `p_val_adj`. There is no separate methods worksheet. Custom XML inspected is Office/SharePoint metadata, not analysis documentation.

Worksheet data-row dimensions (header excluded; not significant-DEG counts): B intermediate 52; B memory 32; B naive 48; CD4 CTL 341; CD4 Naive 30; CD4 TCM 59; CD4 TEM 22; CD8 Naive 13; CD8 TCM 11; CD8 TEM 22; CD14 Mono 316; CD16 Mono 973; cDC2 353; dnT 855; Eryth 3142; gdT 63; HSPC 510; ILC 645; MAIT 56; NK CD56 bright 362; NK 119; pDC 2519; Plasmablast 2292; Platelet 793; Treg 69.

**Metadata and documented versus inferred methods**
The workbook filename explicitly identifies a PostvsPre contrast. h5ad `obs/Status_batch` categories are `Post-AAV` and `Pre-AAV`; obs also has Status, donor, sample_id, origin, and cluster fields. There are 41,465 observations. Gene symbols are in `var/_index` and Ensembl IDs in `var/gene_ids`. Metadata were read directly with h5py; no expression matrix was loaded.
Stored h5ad DEG parameters include Wilcoxon, Benjamini–Hochberg correction, and reference `rest`, with grouping by `clusters_gex_for_degs` or `test`. These are cluster/bicluster comparisons and do NOT document the workbook's post-versus-pre testing method. I will not transfer those parameters to the workbook. No explicit workbook significance cutoff, effect-size cutoff, paired-donor model, adjustment method, or definition of pct.1/pct.2 was found. `avg_log2FC` denotes the supplied log2 fold change; interpreting positive values as post-treatment increases follows the filename but is not independently documented. Direction is unnecessary for counting DEGs in either direction.

**Proposed implementation after approval**
Retain and execute `analysis/identify_top_immune_degs.py`. It will read every worksheet, rename the first column `gene`, verify schemas, trim gene identifiers without changing case or collapsing aliases, and coerce significance/fold-change fields to numeric. Record missing identifiers, missing/nonfinite/out-of-range p-values, duplicates, and inconsistent duplicate statistics. Exclude missing/blank identifiers and invalid adjusted p-values from the primary counts; valid zero p-values remain valid. Count distinct gene symbols satisfying the criterion within each sheet, not rows; exact duplicates cannot inflate counts. If nonidentical duplicate gene entries occur, report them and count the gene once if any valid entry qualifies, with a conservative all-entries check if consequential.

Primary criterion: supplied `p_val_adj < 0.05`, in either fold-change direction, without a newly imposed effect-size filter. This cutoff and the absence of an additional effect-size requirement are explicit assumptions, not documented methods. Use the existing adjustment, not a fresh correction over the displayed rows. Missing fold change does not invalidate an otherwise valid adjusted-p primary count, but is flagged and excluded from effect-size sensitivity counts. Sensitivity checks will compare adjusted cutoffs 0.01 and 0.05, inclusion of the equality boundary, and an additional |avg_log2FC| > 0.25 filter, clearly labeled exploratory conventions rather than recovered methods.

Primary immune ranking excludes Eryth and Platelet as nonimmune lineages, and HSPC as progenitors rather than mature immune cells. Keep all sheets in an audit table and check whether including HSPC changes the leader. The remaining B, T, NK, dendritic, monocyte, ILC, MAIT, and plasmablast sheets remain eligible. Produce a per-sheet audit/count CSV and a ranked immune table, report ties if any, and answer concisely with the leading cell type and count under the declared rule. No reanalysis of expression data is needed.

**Consequential uncertainties**
The cutoff, effect-size requirement, and workbook upstream prefiltering are undocumented. Some displayed rows are demonstrably nonsignificant, so sheet size is not a DEG count. Counts will describe genes represented in these supplied tables, not guarantee coverage of every tested gene. The workbook correction method and donor modeling cannot be recovered from the inspected metadata. HSPC classification and conflicting duplicates will be explicitly audited. Awaiting approval before calculating rankings or creating/executing the main analysis artifact.
````

**Stage**

````text
plan
````

**Evidence**

````text
All 25 worksheets share the same six-column header. Example: CD4 TEM's second displayed data row is IFI6 with p_val_adj=0.734139144112407, whereas its first is GAPDH with p_val_adj=2.80544723497156e-07; therefore tables are not uniformly adjusted-significant gene lists. h5ad Status_batch categories are Post-AAV and Pre-AAV; stored degs_for_gex_clusters parameters are groupby=clusters_gex_for_degs, reference=rest, method=wilcoxon, corr_method=benjamini-hochberg. No full expression arrays were accessed.
````

**Assumptions**

````text
[
  "Primary statistical significance is supplied p_val_adj < 0.05.",
  "No additional effect-size filter is required absent explicit documentation.",
  "Count unique gene symbols per sheet; classify HSPC separately from mature immune cells."
]
````

**Uncertainties**

````text
[
  "Workbook testing and multiple-testing methods are not explicitly documented by the supplied metadata.",
  "Workbook upstream gene selection and contrast direction coding are not fully documented.",
  "Cutoff, effect-size filtering, duplicate behavior, and HSPC eligibility could affect the final ranking."
]
````

### Event 11 — Simulator

**Message**

````text
Approved. Execute the proposed workbook-based analysis and retain analysis/identify_top_immune_degs.py plus the audit and ranking outputs. Use unique genes with supplied p_val_adj < 0.05 as the primary criterion, counting both directions without an additional effect-size threshold; explicitly label these choices as assumptions. The proposed nonimmune exclusions, separate HSPC check, validation of identifiers and adjusted p-values, duplicate audit, and limited sensitivity checks are appropriate. Do not infer the workbook's correction or testing method from unrelated h5ad comparisons. Report the leading immune cell type, its count, the nearest competing counts, and whether the sensitivity checks change the leader; surface any consequential duplicate or data-quality issue. Provide a concise final candidate with stage=final, answer, payload.executed_analysis=true only after execution, and artifacts.analysis pointing to the retained executed script.
````

**Interaction**

````text
next_task
````

**Phase**

````text
approach_review
````

**Action**

````text
continue
````

**Approve Approach**

````text
true
````

**Evidence**

````text
Inspection reports a common gene and adjusted-p schema across 25 sheets, with nonsignificant rows present, so worksheet sizes cannot answer the question. The supplied post-versus-pre workbook supports a direct count analysis; its statistical thresholds and upstream methods remain undocumented, and the proposed approach appropriately keeps those assumptions explicit.
````

**Objectives Open**

````text
[
  "Execute validated significant-gene counts and identify the highest-ranking immune cell type.",
  "Report diagnostics and sensitivity of the leader to the declared thresholds and eligibility choices.",
  "Return a concise final answer with the executed analysis artifact."
]
````

### Event 14 — Actor

**Answer**

````text
Final candidate: CD14 monocytes (CD14 Mono) have the most significantly differentially expressed genes after AAV9 mini-dystrophin treatment: 315 unique genes using supplied adjusted p-values < 0.05, counting both directions without an additional fold-change threshold. CD16 monocytes follow with 240, then NK cells with 118.
````

**Stage**

````text
result
````

**Evidence**

````text
Executed python analysis/identify_top_immune_degs.py successfully (exit code 0). Primary counts: CD14 Mono 315, CD16 Mono 240, NK 118, CD4 TCM 58, B intermediate 36. At adjusted p < 0.01, the top three counts are 314, 187, and 118 respectively; CD14 Mono remains first. Using adjusted p <= 0.05 or adding |avg_log2FC| > 0.25 leaves all primary counts unchanged. Including HSPC (18 significant genes) does not change the leader. Excluded Eryth and Platelet each have zero significant genes. Across all 25 worksheets: zero missing/blank gene identifiers, zero invalid/missing adjusted p-values, zero missing/nonfinite fold changes, zero duplicate gene rows, and zero conflicting duplicate genes. Audit, ranking, duplicate audit (header-only because none found), and summary files were retained alongside the executed nonempty script.
````

**Assumptions**

````text
[
  "Significance is defined as supplied p_val_adj < 0.05; this cutoff is assumed, not documented in the supplied workbook.",
  "Both fold-change directions are counted without an additional effect-size requirement; this is an approved assumption.",
  "Eryth and Platelet are excluded as nonimmune lineages; HSPC is evaluated separately from mature immune cells."
]
````

**Uncertainties**

````text
[
  "Counts are restricted to genes represented in the supplied workbook; upstream gene prefiltering is undocumented.",
  "The workbook's testing method, multiple-testing correction method, and donor modeling are not established by the supplied metadata. Unrelated h5ad cluster comparisons were not used to infer these methods."
]
````

### Event 15 — Simulator

**Message**

````text
The reported analysis adequately answers the question. Submit the final candidate: CD14 monocytes (CD14 Mono), with 315 significantly differentially expressed genes after treatment using supplied adjusted p < 0.05 and no additional fold-change threshold. Retain stage=final, payload.executed_analysis=true, and artifacts.analysis="analysis/identify_top_immune_degs.py".
````

**Interaction**

````text
conclude
````

**Phase**

````text
result_review
````

**Action**

````text
stop
````

**Approve Approach**

````text
false
````

**Evidence**

````text
The agent reports successful script execution, unique-gene counts led by CD14 Mono (315) over CD16 Mono (240) and NK (118), no consequential data-quality or duplicate issues, and an unchanged leader across the agreed sensitivity checks. The final candidate includes the required execution flag and analysis artifact path. Undocumented upstream methods remain appropriately qualified rather than inferred.
````

**Objectives Open**

````text
[]
````

## Provenance

````text
{
  "source_run": "runs/openai-astra-top2-first-pass",
  "repair_run": "runs/repair-1-openai-astra-top2-first-pass",
  "event_log": "runs/openai-astra-top2-first-pass/episodes/bixbench_bix-33-q1-f703710d5b2b/persona_off/attempt-1/output/bixbench_bix-33-q1-f703710d5b2b/controller/events.jsonl",
  "event_log_sha256": "53df032c9cae0b740bcbbc788bbf388cf8bb3a8f1186874e937d816ae22f8e3e",
  "models": {
    "actor": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "researcher": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "judge": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    }
  }
}
````
